Please assess the completion status of the following clinical trial:

Trial Title: A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Main Inclusion at Screening (Visit 1):~* Subject had completed study 178-CL-101 or study 905-EC-012 (This inclusion criterion would no longer apply once the recruitment for study 178-CL-101 and study 905-EC-012 had been completed. In that case the subject had to have symptoms of wet OAB (urinary frequency and urgency with incontinence) for at least 3 months);~* Subject was willing and able to complete the micturition diary and questionnaires correctly and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;~Main Inclusion at Randomization (Visit 2):~* Subject had a micturition frequency of on average ≥ 8 times per 24-hour period during the last 7 days of the micturition diary period (incontinence episode should not be counted as a micturition).~* Subject had experienced at least 3 incontinence episodes during the last 7 days of the micturition diary period.~* Subject had experienced on average at least 1 urgency episode (grade 3 or 4 on Patient Perception of Intensity of Urgency Scale \[PPIUS\]) per 24-hour period during the 7-day micturition diary period.~Exclusion Criteria:~Main Exclusion at Screening (Visit 1):~* Subject had clinically significant bladder outflow obstruction at risk of urinary retention;~* Subject had significant PVR volume (\> 150 mL);~* Subject had significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor;~* Subject has an indwelling catheter or practices intermittent self-catheterization;~* Subject had evidence of a UTI (urine culture containing \> 100,000 cfu/mL), chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;~* Subject had intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin;~Main Exclusion at Randomization (Visit 2):~* Subject had evidence of a urinary tract infection (UTI) (urine culture containing \> 100,000 cfu/mL) as assessed in the Screening visit (V1) samples. The subject could be rescreened after successful treatment of the UTI (confirmed by a dipstick negative for nitrite).~* Subject had an average total daily urine volume \> 3000 mL as recorded in the micturition diary period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirabegron 50 mg (Type: ACTIVE_COMPARATOR): Participants received mirabegron 50 mg once a day for 52 weeks.
- Solifenacin 5 mg (Type: ACTIVE_COMPARATOR): Participants received solifenacin 5 mg once a day for 52 weeks.
- Solifenacin 5 mg + Mirabegron 50 mg (Type: EXPERIMENTAL): Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).